TheraCryf approves £1.05m capital raise and share-capital reorganisation

TheraCryf confirmed on 7 September 2026 that shareholders approved its approximately £1.05m gross capital raise and the related subdivision of share capital.

Shares and dates

The placing and subscription will issue 583,333,328 new ordinary shares. Admission is expected on 9 September, after the subdivision record time of 6pm on 8 September.

Each existing 0.25p ordinary share becomes one 0.05p ordinary share plus four 0.05p deferred shares. The deferred shares have no voting or dividend rights and will not trade on AIM. This is not a fivefold increase in economically equivalent ordinary shares.

After admission, the company expects 2,732,297,067 ordinary shares and voting rights. New fundraising shares represent approximately 21.35% of that enlarged total, calculated from the disclosed figures.

Why it matters

Approval removes a shareholder condition for the fundraising and supports the development programme. Existing holders still face dilution from the new ordinary shares.

The next checkpoints are admission, net proceeds after expenses and progress toward clinical readiness. Financing approval is distinct from regulatory approval or evidence that a medicine works in patients.

Source: Company announcement, 7 September 2026.